Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

• ClinicalTrials.gov Identifier: NCT00546156
• Recruitment Status: Completed
• First Posted: October 18, 2007
• Results First Posted: May 10, 2013
• Last Update Posted: May 18, 2021
• Sponsor: Ian E. Krop, MD, PhD
• Collaborators: Genentech, Inc.; Massachusetts General Hospital; Brigham and Women's Hospital; New Hampshire Oncology-Hematology PA
• Information provided by (Responsible Party): Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute

Study Description

Brief Summary:

Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment of ER+ or PR+ breast cancer. In this trial, the standard chemotherapy is being combined with bevacizumab. Bevacizumab is an antibody which works differently from the way other chemotherapy drugs work. Bevacizumab slows or stops cell growth in cancerous tumors by decreasing the blood supply to the tumors by binding to a substance found on cancer cells called VEGF (vascular endothelial growth factor). Bevacizumab is approved by the FDA for the treatment of colorectal cancer and lung cancer. However, it is not approved for the treatment of breast cancer. Another goal of this research is to determine whether we can develop a way to identify tumors that will respond well to this study treatment.

Condition or disease	Intervention/treatment	Phase
Breast Cancer	Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Paclitaxel; Drug: Bevacizumab	Phase 2

Detailed Description:

• To prepare for the surgery that will occur at the end of the study treatment, a small "clip" will be placed into the tumor area so that the surgeon can locate the site of the tumor at the time of surgery. This is a standard procedure for breast cancer.
• During the clip placement, a needle will be inserted into the tumor to measure interstitial fluid pressure (IFP measurement). IFP is done for research purposes to help understand how the tumor responds to the study treatment.
• Study treatment will begin with one dose of bevacizumab alone, followed two weeks later by chemotherapy and bevacizumab in eight two-week cycles. The study treatment will be given intravenously in the clinic.
• After the first dose of bevacizumab and prior to starting chemotherapy, a needle biopsy of the breast tumor will be performed for research purposes. A second measurement of IFP will also be done at this time.
• During the treatment period, tests and procedures will be performed at specified intervals and include the following: research MRI, physical exams, blood tests, urine tests, EKG, and MUGA or ECHO.
• Surgery to remove the tumor will occur no less than four weeks after the last dose of Paclitaxel.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 104 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
• Study Start Date: October 2007
• Actual Primary Completion Date: October 2011
• Actual Study Completion Date: December 2012

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: HR+, HER2-; Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.	Drug: Doxorubicin; Standard chemotherapy regimen; Other Name: Adriamycin; Drug: Cyclophosphamide; Standard chemotherapy regimen; Other Name: Cytoxan; Drug: Paclitaxel; Standard chemotherapy regimen; Other Name: Taxol; Drug: Bevacizumab; One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.; Other Name: Avastin
Active Comparator: Triple Negative Breast Cancer Cohort; Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.	Drug: Doxorubicin; Standard chemotherapy regimen; Other Name: Adriamycin; Drug: Cyclophosphamide; Standard chemotherapy regimen; Other Name: Cytoxan; Drug: Paclitaxel; Standard chemotherapy regimen; Other Name: Taxol; Drug: Bevacizumab; One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.; Other Name: Avastin

Outcome Measures

Primary Outcome Measures :

1. Pathologic Complete Response Rate After Preoperative Therapy in This Patient Population. [ Time Frame: 3 Years ]
   Pathological Complete response is defined as complete disappearance of invasive tumor in the breast at the time of surgery

Secondary Outcome Measures :

1. Decrease in Interstitial Fluid Pressure. [ Time Frame: 3 years ]
   To determine if bevacizumab monotherapy results in a decrease in interstitial fluid pressure

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Documented primary invasive breast cancer by histologic assessment
• Tumors must express estrogen (ER) and/or progesterone receptors (PR) by standard immunohistochemical methods. Tumors must be negative for HER2. There must be sufficient sample for further protocol-specified immunohistochemical analysis
• Patients must have high risk ER+ or PR+ breast cancer as defined by criteria listed in protocol
• 18 year of age or older
• Performance status of 0 or 1 by ECOG criteria
• Use of an effective means of contraception in subjects of childbearing potential
• Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to starting therapy.
• Patients taking exogenous sex-steroid hormone treatments for any reason at the time of diagnosis must discontinue all hormonal treatments at least 2 weeks prior to enrollment
• Patients must have preoperative treatment within 60 days of initial diagnosis of breast cancer
• No other malignancy that requires on-going treatment
• Normal organ function as outlined in the protocol

Exclusion Criteria:

• Prior cytotoxic chemotherapy or radiation for the current breast cancer
• Patients with inflammatory breast cancer
• HER2 positive disease defined as HER2-amplified by FISH or IHC 3+. HER2 2+ must be negative by FISH
• Known metastatic (Stage IV) disease
• Other investigational agents within 4 weeks prior to the start of study treatment
• Life expectancy of less than 6 months
• Peripheral neuropathy greater than or equal to grade 2
• Inadequately controlled hypertension
• Any prior history of hypertensive crisis or hypertensive encephalopathy
• NYHA grade II or greater congestive heart failure
• History of prior myocardial infarction
• History of unstable angina within 12 months prior to study enrollment
• Any history of stroke or transient ischemic attack at any time
• Known CNS disease
• Significant vascular disease
• Symptomatic peripheral vascular disease
• Evidence of significant bleeding within 6 months of study; any serious non-healing wound, skin ulcers, or bone fracture; any abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within the past 6 months; any major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during course of study.
• Known HIV positive
• Unwilling to undergo pretreatment biopsy and consent to acquisition of archival tissue
• Pregnant of lactating
• Known hypersensitivity to any component of bevacizumab

Contacts and Locations

Locations

United States, Massachusetts

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

Dana-Farber at Faulkner Hospital

Boston, Massachusetts, United States, 02130

United States, New Hampshire

New Hampshire Oncology-Hematology PA

Hooksett, New Hampshire, United States, 03106

Sponsors and Collaborators

Ian E. Krop, MD, PhD

Genentech, Inc.

Massachusetts General Hospital

Brigham and Women's Hospital

New Hampshire Oncology-Hematology PA

Investigators

• Principal Investigator: Ian Krop, MD, PhD; Dana-Farber Cancer Institute

More Information

• Responsible Party: Ian E. Krop, MD, PhD, Medical Oncologist, Dana-Farber Cancer Institute
• ClinicalTrials.gov Identifier: NCT00546156
• Other Study ID Numbers: 07-130
• First Posted: October 18, 2007
• Results First Posted: May 10, 2013
• Last Update Posted: May 18, 2021
• Last Verified: April 2021

Keywords provided by Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute:

ER positive; PR positive

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Paclitaxel; Cyclophosphamide; Bevacizumab; Doxorubicin; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Antibiotics, Antineoplastic; Topoisomerase II Inhibitors; Topoisomerase Inhibitors